A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer Non-small Cell Lung Cancer or Melanoma A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer Non-small Cell Lung Cancer or Melanoma That Has Spread to the Brain
Brief description of study
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.
Clinical Study Identifier: s15-00690
ClinicalTrials.gov Identifier: NCTs15-00690
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
